Indian Regulator Warns Pharma Firms Not To Miss Expert Panel Meetings
This article was originally published in SRA
Executive Summary
The failure of certain drug companies to turn up at meetings organized to review their products by subject matter experts has irked the Drugs Controller General of India, who has warned that such unexplained absences are "viewed seriously"1.